Background:
Selatogrel
Outcome
Study
in
suspected
Acute
Myocardial
Infarction
(SOS-AMI)
Multi-center,
double-blind,
randomized,
placebo-controlled,
parallel-group
study
to
evaluate
the
efficacy
and
safety
of
self-administered
subcutaneous
selatogrel
for
prevention
of
all-cause
death
and
treatment
of
acute
myocardial
infarction
in
subjects
with
a
recent
history
of
acute
myocardial infarction
EudraCT Number:
2020-000983-41 (clinicaltrials.gov) Link
Sponsor:
Idorsia Pharmaceuticals Ltd
Trial Status:
Recruiting
Enrolling Centers:
Worldwide:
250/ 20 – 30 countries/ 14000 participants
Core Study Team Basel:
© Christian Mueller, 2012 - 2023 │ Disclaimer │ Imprint │ Webmaster │ Last Update: April 2024
SOS-AMI
